Physician

David Jon Tamura, M.D.

According to 2025 Medicare claims, David Tamura, M.D. (NPI: 1295953123) practices hematology/oncology in the Urban Honolulu, HI market, with the plurality of this provider's patient population coming from Honolulu, HI. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS OF HAWAII, LLC (NPI: 1629835814; TIN: 991656366) and primary practice location at 96813-4929.

Tamura's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 515 traditional Medicare patients, billed 74,976 HCPCS/CPT codes, and received $1,808,982 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,084 prescription claims across 378 beneficiaries totaling $11,935,147 in drug costs, led by Tagrisso (Osimertinib Mesylate). DME data shows 42 claims. Open Payments data shows 144 records totaling $4,010. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $963,324 and ending at $1,808,982. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,223,105 to $11,935,147. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	264	35,735	$963,324
2016	326	59,409	$851,593
2017	336	89,946	$875,533
2018	344	50,147	$659,687
2019	350	50,781	$1,736,294
2020	365	52,415	$724,783
2021	590	148,100	$2,919,438
2022	544	124,178	$2,297,443
2023	543	28,589	$399,943
2024	515	74,976	$1,808,982

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	162	803	$1,223,105
2016	186	892	$1,825,526
2017	197	1,257	$3,118,523
2018	229	1,659	$4,205,519
2019	261	1,728	$5,257,459
2020	233	1,720	$5,658,913
2021	335	2,286	$7,799,490
2022	335	2,602	$9,332,023
2023	369	3,267	$11,883,030
2024	378	3,084	$11,935,147

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	43	$4,852
2016	N/R	58	$21,466
2017	N/R	35	$11,854
2018	N/R	83	$17,201
2019	N/R	N/R	N/R
2020	N/R	32	$3,101
2021	N/R	N/R	N/R
2022	N/R	37	$1,253
2023	N/R	52	$9,955
2024	N/R	42	$933

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	373	1,137	$97
80048	Blood test, basic group of blood chemicals (calcium, total)	232	561	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	323	1,121	$8
36415	Insertion of needle into vein for collection of blood sample	329	1,141	$7
83615	Lactate dehydrogenase (enzyme) level	242	409	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	115	3,450	$1,990,976
Xtandi	Enzalutamide	90	2,760	$1,114,621
Keytruda	Pembrolizumab	70	1,533	$906,526
Nubeqa	Darolutamide	68	2,040	$843,690
Xgeva	Denosumab	181	5,512	$579,484

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$532
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$263
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$138

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	144	$4,010	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David Jon Tamura, M.D.?

Tedicare shows public-source Medicare data for David Jon Tamura, M.D. (NPI 1295953123), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David Jon Tamura, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to David Jon Tamura, M.D.?

David Jon Tamura, M.D. is linked to AMERICAN ONCOLOGY PARTNERS OF HAWAII, LLC (billing NPI 1629835814) in the available physician profile data.

Does David Jon Tamura, M.D. have Open Payments data?

David Jon Tamura, M.D. has 144 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.